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Abstract
Background: Celiac disease, Crohn disease and ulcerative colitis are inflammatory disorders of the gastrointestinal
tract with some common genetic, immunological and environmental factors involved in their pathogenesis. Several
research shown that patients with celiac disease have increased risk of developing inflammatory bowel disease when
compared with that of the general population. The aim of this study is to determine the prevalence of inflammatory
bowel disease in our celiac patient cohort over a 15-year-long study period.
Methods: To diagnose celiac disease, serological tests were used, and duodenal biopsy samples were taken to determine
the degree of mucosal injury. To set up the diagnosis of inflammatory bowel disease, clinical parameters, imaging
techniques, colonoscopy histology were applied. DEXA for measuring bone mineral density was performed on every
patient.
Results: In our material, 8/245 (3,2 %) coeliac disease patients presented inflammatory bowel disease (four males, mean
age 37, range 22–67), 6/8 Crohn’s disease, and 2/8 ulcerative colitis. In 7/8 patients the diagnosis of coeliac disease was
made first and inflammatory bowel disease was identified during follow-up. The average time period during the set-up of
the two diagnosis was 10,7 years. Coeliac disease serology was positive in all cases. The distribution of histology results
according to Marsh classification: 1/8 M1, 2/8 M2, 3/8 M3a, 2/8 M3b. The distribution according to the Montreal
classification: 4/6 Crohn’s disease patients are B1, 2/6 Crohn’s disease patients are B2, 2/2 ulcerative colitis patients are S2.
Normal bone mineral density was detected in 2/8 case, osteopenia in 4/8 and osteoporosis in 2/8 patients.
Conclusions: Within our cohort of patients with coeliac disease, inflammatory bowel disease was significantly more
common (3,2 %) than in the general population.
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Background
According to the ESPGHAN definition, “Coeliac disease
is an immune-mediated systemic disorder elicited by
gluten and related prolamines in genetically susceptible
individuals, characterised by the presence of a variable
combination of gluten dependent clinical manifestations,
coeliac disease specific antibodies, HLA-DQ2 and DQ8
haplotypes and enteropathy” [1]. However, coeliac dis-
ease (CeD) may occur at any age, with the potential
involvement of any organs. The prevalence of CeD in
Hungarian population ranges from 1 to 1,5 % [2]. In
adulthood, “classic symptoms” including diarrhea, abdom-
inal distension, malabsorption syndrome are frequently
absent. Patients may exhibit minor gastrointestinal com-
plaints, as well as numerous extraintestinal manifestations.
For the diagnosis of CeD in dietary naive adult patients
serological and histological examination are necessary.
After diagnosis, the basis of all the present treatments for
CeD is the life-long gluten-free diet.
Nowadays, the range of diseases that can be proven to
occur more frequently in untreated CeD has expanded.
Various autoimmune diseases show association with
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CeD, such as type-1 diabetes mellitus, autoimmune thy-
roid disorders, selective IgA-deficiency, autoimmune
hepatitis Sjögren’s syndrome, juvenile chronic arthritis
and the cutaneous form of celiac disease Dermatitis her-
petiformis Duhring (DHD).
CeD and inflammatory bowel disease (IBD) are inflam-
matory disorders of the gastrointestinal tract with some
common genetic, immunological and environmental fac-
tors involved in their pathogenesis. Several research
showed that patients with CeD have a 5–10-fold risk of
developing IBD when compared with that of the general
population.
Fifteen years ago, an adult CeD centre was founded at
Semmelweis University, 2nd Department of Internal
Medicine, aiming to diagnose, care and follow-up CeD
patients in a uniform manner. The number of treated
adult patients has reached 300 by 2015, 50 % from
Budapest and 50 % from the countryside. Thanks to the
numerous presentations and publications on the activity
of this adult CeD centre nationwide, this adult centre
has gradually become a referral centre accepted and
seeked by every gastroenterology outpatient settings in
Hungary. Focusing on the closer region of our centre,
the proportion of celiac patients ever recorded in this
centre is estimated to be 30–40 % of all adult celiac pa-
tients diagnosed and living in the central region of
Hungary, with a total number of inhabitants of approxi-
mately 2.5 million people. Concerning IBD, the same de-
partment is one of the 11 centres of Hungary, having a
state permission to provide IBD patients with biological
therapy. The aim of this study was to establish the
prevalence of IBD in our coeliac centre over a 15-year-
long study period.
Methods
Our study is a retrospective analysis. The data collection,
processing and evaluating of the results were performed
according to the existing legislation and in accordance
with the Declaration of Helsinki. According to Hungar-
ian guidelines no special ethical approval was required
for this retrospective study.
Results of totally 248 patients with CeD attending the
coeliac centre of 2nd Department of Medicine at
Semmelweis University from November of 1997 till
November of 2013 were analysed. There were 193 fe-
male and 55 male patients (78 % vs. 22 %), with a mean
age of 38 years, a median of 37 years and a range be-
tween 19 and 80 years. Of note, being a referral centre,
in some cases, the diagnostic work-up of patients were
launched in the primary care or at other settings. These
patients were then referred to our centre for revision
and confirmation of the suspected diagnosis. In order to
diagnose CeD, tissue transglutaminase antibody testing
(tTG; IgA and IgG normal range: 0–10 U/ml) and/or
endomysium antibody tests (EMA) were used for ser-
ology. The IgG-tTG result was applied for cases of se-
lective IgA-deficiency. Serological tests were carried out
at Semmelweis University and the Coeliac Disease Cen-
ter of Heim Pal Children’s Hospital. Duodenal biopsy
samples were taken to determine the degree of mucosal
injury described according to the modified Marsh classi-
fication. Histological evaluation was performed mostly at
the 1st Department of Pathology and Experimental Can-
cer Research of the Semmelweis University.
To set up the diagnosis of IBD, clinical parameters,
imaging techniques, colonoscopy, video capsule endos-
copy and histology were applied. Dual energy X-ray ab-
sorptiometry for measuring bone mineral density (BMD)
was performed on every patient. Statistical analysis was
conducted using GraphPad InStat 3.0® (San Diego, CA)
software.
Results
In our material, 8/245 (3,2 %) CeD patients presented
IBD. There were four males and four females, the mean
age was 37 years, range 22–67 years. Crohn’s disease
(CD) was present in 6/8 patients (three male, three fe-
male). Ulcerative colitis (UC) was present in 2/8 patients
(one male, one female). In 7/8 patients the diagnosis of
CeD was made first and IBD was identified during
follow-up. The average time period during the setup of
the two diagnosis was 10,7 years (median: 5 years, range
4–535 months). All the eight patients with both IBD and
CeD had serologic evidence of CeD at time of initial
diagnosis. Serological tests were performed with tTG
in 2/8 cases, and EMA in 6/8 cases. The distribution
of duodenal histology results according to Marsh-
Oberhuber classification were 1/8 M1, 2/8 M2, 3/8
M3a, 2/8 M3b. The distribution according to the
Montreal classification: 4/6 CD patients are B1 (non-
stricturing, nonpenetrating) and 2/6 patients are B2
(stricturing), 2/2 UC patients are S2 (moderate UC).
Biological therapy (infliximab) was administered to 2/
8 patients. One patient had selective IgA deficiency,
and one patient also suffered from DHD. Osteodensi-
tometry was performed on every patient with CeD
and IBD. Normal BMD was detected in 2/8 case (1/2
CD, 1/2 CU), osteopenia in 4/8 patients (2/4 CD, 2/4
CU), and osteoporosis in 2/8 patients (2/2 CD). The
mean body mass index (BMI) was 21,53 kg/m2, range
17,28–23,94 kg/m2. Mean BMI for males was 22,25
and 20,74 kg/m2 for females, respectively (Table 1).
All but one CeD-IBD patient had their CeD earlier
diagnosed, than IBD; anemia was presented in totally
four patients, diarrhea in two patients, loss of weight
in two patients and one DHD in one patient, respect-
ively. There was only 1/8 patient whose IBD was earl-
ier diagnosed, in his case serological screening aimed
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at several other autoimmune disorder resulted tTG
positivity.
Discussion
Several autoimmune diseases are associated with CeD.
To date, no conclusive evidence is available that proves
if the relationship between CeD and autoimmune dis-
eases is mediated by gluten exposure, or if CeD and
autoimmune diseases could occur together due to other
causes, particularly the injury of the integrity of the
intestinal barrier function and the common genetic
background (Table 1) [3]. Genetic studies have identified
four shared risk chromosomal loci: PTPN2, IL18RAP,
TAGAP, and PUS10 in both diseases [4]. This consider-
able overlap between the associated genetic regions
might indicate partial agreement of the pathogenesis
both of these diseases. Patients with IBD and CeD have
number of common symptoms like diarrhea, malabsorp-
tion, weight loss, long-standing history of iron deficiency
anaemia, and loss of BMD and this could cause prob-
lems in the diagnostics [5–7].
The prevalence of CeD (1:100) multiply exceeds that
of IBD (CD 0,1–16:104, UC 0,5–25:104) in general popu-
lation [8]. Previous studies showed, that the prevalence
of IBD is 5–10 times higher in CeD compared with that
of the general population [9–12].
In our cohort of patients with CeD the prevalence
of IBD was 3,2 %. Other studies carried out among
adult coeliac patients also found a similar prevalence
of IBD. Yang et al. reported the prevalence of IBD to
be 2,20 % in a cohort of 455 CeD patients [13].
Leeds at al. presented an IBD prevalence of 3,30 %
among 305 CeD patients, however the prevalence of
CeD among IBD patients was comparable with that
of the controls [14]. Furthermore, Casella et al.
found lower risk of CeD in their cohort of IBD pa-
tients than in the general population [15]. Assumed
cause of this difference is that the increased intes-
tinal permeability in CeD may lead to increased
antigen presentation and therefore generation of
autoantibodies or increased bacterial translocation,
which has been involved in IBD as a pathogenic
mechanism [14, 16].
In our study, CD was more common than UC in a co-
hort of IBD patients. In contrast to our results, CeD
were reported more frequently to be associated with UC
than CD [10, 17–19]. Moreover, two further studies
reported high prevalence of UC even among the first-
degree relatives of patients with CeD [20, 21].
The average time period during the setup of the two
diagnosis in our patients’ cohort was 10,7 years, this re-
sult correspond well with the results from a previous
study [13].
In our setting, in patients with both CeD and IBD,
initial CeD serological testing were performed in
most of the cases with EMA, which are highly spe-
cific for CeD and are not found in IBD [22]. tTG
can be false positive in some chronic disorders such
as type 1 diabetes mellitus and chronic liver diseases.
Di Tola et al. and Farrace et al. both detected in-
creased tTG IgA antibodies levels in patients with
CD and UC [23, 24]. These results suggest positive
tTG autoantibodies may be a phenomen of auto-
immunity and loss of specificity in CeD [25].
At the time of the diagnosis, the majority of our pa-
tients the duodenal biopsies presented low stage (M1,
M2, M3a) according to Marsh-Oberhuber classification.
Histological findings of Marsh 1 were consider not fully
sufficient for the diagnosis of CeD, but the one of our
patient, how presented M1 stage also had biopsy-proof
Dermatitis herpetiformis Duhring, which is the skin
manifestation of CeD. Casella and his colleagues ob-
served similar distribution of histological results [15].
However, number of studies has found intraepithelial
lymphocytosis and villous atrophy in CD patients with-
out any evidence of CeD [26–28]. This histological sta-
tus makes it difficult to differentiate CeD from CD.
In our patients’ cohort, the dominant behaviour of IBD
was of the inflammatory type, which is in line with data
in literature [14, 15, 29].
Table 1 Clinical characteristics of patients with inflammatory bowel disease and celiac disease
Patients Initial diagnosis Second diagnosis Time to second diagnosis Coeliac
serology
Marsh-
classification
Montreal-
classification
BMD (bone mineral
density)
1 Crohn’s disease Coeliac disease ~4 month tTG + M2 A2L3B1 osteopenia.
2 Coeliac disease Ulcerative colitis ~9 month tTG + M3a A2E3S2 osteopenia
3 Coeliac disease Crohn’s disease ~8 years (96 month) EMA + M3b A2L3B2 normal
4 Coeliac disease Crohn's disease ~20 years (240 month) EMA + M1 A3L1B1 osteoporosis
5 Coeliac disease Crohn's disease ~5 years 5 month (65 month) EMA + M3a A2L2B2 osteopenia
6 Coeliac disease Crohn's disease ~5 years (60 month) EMA + M2 A2L3B1 osteopenia
7 Coeliac disease Crohn's disease ~44 years 7 month (535 month) EMA + M3b A3L1B1 osteoporosis
8 Coeliac disease Ulcerative colitis ~2 years 1 month (25 month) EMA + M3a A2E2S2 normal
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In our study, the mean body mass index value of
21,53 kg/m2 also falls within the normal range provided
by the WHO. Unlike coeliac children, the vast ma-
jority of adult coeliacs are not malnourished, even
overweight patients are not uncommon [30, 31].
However, malnutrition is a common feature of adult
IBD [32]. In contrast to our results, low range of
BMI in patients with both CeD and IBD has been
reported [33–35].
IBD and CeD are associated with an increased risk
of loss on BMD, caused by malabsorption and in-
flammation. Prevalence of osteoporosis were shown
to be 7–35 % in CD patients, 18 % in UC patients,
and 36–38 % in untreated in CeD patients, respect-
ively [36–40]. Interestingly, the loss of BMD in our
patients with two different disease potentially leading
to malabsorption syndrome were not worse than for those
suffering in only one of these disorders.
Conclusions
In conclusion, within our cohort of patients with
CeD, IBD was significantly more common (3,2 %)
than in the general population. On this basis celiac
disease patients can be considered as a new potential
inflammatory bowel disease risk group. Diagnosis of
CeD mostly preceded the diagnosis of IBD. The
dominant behaviour of IBD was of the inflammatory
type. In our study, CD was more common than UC
among patients suffering from CeD. The mean BMI
value of our sample is within normal range. The loss
of BMD for our patients with CeD and CD were not
worse than for those suffering in only one of these
disorders.
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